Busulfan
Common brands: Busulfex, Myleran, Fludarabine, Cyclophosphamide, Frindovyx
Top reporter: Otsuka America Pharmaceutical, Inc.
Alkylating Drug [EPC]Calcineurin Inhibitor Immunosuppressant [EPC]Folate Analog Metabolic Inhibitor [EPC]Corticosteroid [EPC]Nucleoside Metabolic Inhibitor [EPC]
18,029
Total Reports
10,274
Serious Reports
5,582
Death Reports
30
Reported Reactions
Death Report Ratio: High (30.96%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Busulfan.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | OFF LABEL USE | 2,095 | |
| 2 | PRODUCT USE IN UNAPPROVED INDICATION | 1,827 | |
| 3 | MUCOSAL INFLAMMATION | 1,200 | |
| 4 | DRUG INEFFECTIVE | 1,072 | |
| 5 | GRAFT VERSUS HOST DISEASE | 1,052 | |
| 6 | ACUTE GRAFT VERSUS HOST DISEASE | 1,036 | |
| 7 | VENOOCCLUSIVE LIVER DISEASE | 1,034 | |
| 8 | CYTOMEGALOVIRUS INFECTION | 979 | |
| 9 | FEBRILE NEUTROPENIA | 971 | |
| 10 | PYREXIA | 904 | |
| 11 | CHRONIC GRAFT VERSUS HOST DISEASE | 763 | |
| 12 | SEPSIS | 723 | |
| 13 | ACUTE GRAFT VERSUS HOST DISEASE IN SKIN | 667 | |
| 14 | DIARRHOEA | 652 | |
| 15 | INFECTION | 621 | |
| 16 | VENOOCCLUSIVE DISEASE | 611 | |
| 17 | THROMBOCYTOPENIA | 608 | |
| 18 | CYTOMEGALOVIRUS INFECTION REACTIVATION | 593 | |
| 19 | PNEUMONIA | 588 | |
| 20 | RESPIRATORY FAILURE | 523 | |
| 21 | CYSTITIS HAEMORRHAGIC | 496 | |
| 22 | THROMBOTIC MICROANGIOPATHY | 484 | |
| 23 | PANCYTOPENIA | 476 | |
| 24 | NEUTROPENIA | 455 | |
| 25 | NAUSEA | 423 | |
| 26 | STOMATITIS | 403 | |
| 27 | BK VIRUS INFECTION | 396 | |
| 28 | CYTOMEGALOVIRUS VIRAEMIA | 380 | |
| 29 | MULTIPLE ORGAN DYSFUNCTION SYNDROME | 377 | |
| 30 | DEATH | 372 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.